Cite
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
MLA
Smits, Mark M., et al. “Biliary Effects of Liraglutide and Sitagliptin, a 12-Week Randomized Placebo-Controlled Trial in Type 2 Diabetes Patients.” Diabetes, Obesity & Metabolism, vol. 18, no. 12, Dec. 2016, pp. 1217–25. EBSCOhost, https://doi.org/10.1111/dom.12748.
APA
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Nieuwdorp, M., Groen, A. K., Cahen, D. L., & van Raalte, D. H. (2016). Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes, Obesity & Metabolism, 18(12), 1217–1225. https://doi.org/10.1111/dom.12748
Chicago
Smits, Mark M., Lennart Tonneijck, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, Michaela Diamant, Max Nieuwdorp, Albert K. Groen, Djuna L. Cahen, and Daniël H. van Raalte. 2016. “Biliary Effects of Liraglutide and Sitagliptin, a 12-Week Randomized Placebo-Controlled Trial in Type 2 Diabetes Patients.” Diabetes, Obesity & Metabolism 18 (12): 1217–25. doi:10.1111/dom.12748.